Compare HTCR & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTCR | PPBT |
|---|---|---|
| Founded | 2009 | 2010 |
| Country | Japan | Israel |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4M | 2.9M |
| IPO Year | 2022 | 2014 |
| Metric | HTCR | PPBT |
|---|---|---|
| Price | $3.07 | $1.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | 94.5K | ★ 143.1K |
| Earning Date | 05-14-2026 | 05-20-2026 |
| Dividend Yield | ★ 87.84% | N/A |
| EPS Growth | ★ 414.29 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,407,229.00 | N/A |
| Revenue This Year | $123.26 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 39.19 | N/A |
| 52 Week Low | $0.15 | $0.41 |
| 52 Week High | $3.97 | $5.18 |
| Indicator | HTCR | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 48.47 | 29.66 |
| Support Level | $2.80 | $0.57 |
| Resistance Level | $3.86 | $3.09 |
| Average True Range (ATR) | 0.39 | 0.25 |
| MACD | -0.04 | -0.10 |
| Stochastic Oscillator | 11.34 | 22.75 |
HeartCore Enterprises Inc is a software development company providing solutions for digital transformation (DX). It develops, sells, and maintains CMS and CXM platforms using digital marketing technology, RPA, process mining solutions, myInvenio and Apromore, task mining solution CONTROLIO, and 3D-VR services including Matterport and VR360. The company also provides management consulting, education, services, and support to help customers succeed with the CXM Platform. It operates through two business units, the CX division for customer experience management and the DX division for digital transformation, which provides robotics process automation, process mining, and task mining. Its products include VR360, myInvenio, Apromore, and others, with maximum revenue from the United States.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.